Tsze DS, et al. - Researchers undertook this prospective, dose-titration, pilot study to delineate the analgesic efficacy, duration of analgesia, and adverse-event profile associated with intranasal hydromorphone in otherwise healthy children aged 4-17 years with moderate-to-severe pain who require a parenteral opioid. An initial dose of 0.03 mg/kg was given to all patients. An additional 0.015 mg/kg was given to patients, if required, upon assessment at 15 and 30 minutes. They analyzed 35 children. Of these, 15, 11, and 9 children required 0.03, 0.045, and 0.06 mg/kg, respectively. They observed rapid, clinically significant, and frequently sustained decreases in pain intensity in children on reception of intranasal hydromorphone. This preliminary sample exhibited no major adverse events.